Results 131 to 140 of about 18,115 (178)

Overall survival of immunotherapy versus standard of care in chemorefractory microsatellite stable metastatic colorectal cancer: a propensity score matched analysis of 708 patients. [PDF]

J Immunother Cancer
Vetere G, Osterlund E, Yousef MMG, Payapwattanawong S, Maddalena G, Alshenaifi J, Alfaro KD, Knafl M, Morris VK, Parseghian CM, Raghav KPS, Wolff RA, Dasari A, Overman MJ, Kopetz S, Shen JP.   +15 more
europepmc   +1 more source

Second-line TKI after first-line immunotherapy-based treatment in advanced HCC: Reconstructed IPD meta-analysis. [PDF]

JHEP Rep
Akkus E, Hobeika C, Edeline J, Hollande C, Allaire M, Amaddeo G, Regnault H, Lequoy M, Nault JC, Bouattour M.   +9 more
europepmc   +1 more source

Regorafenib-Induced Stress Response Alters the Bioenergetic Profile of Osteosarcoma Cells and Modulates Gene Expression Associated with Metabolic regulation-a Potential Mechanism of Osteosarcoma Treatment-Related Adaptation. [PDF]

Cancer Manag Res
Marcinkowska K, Raciborska A, Obmińska-Mrukowicz B, Śmieszek A.   +3 more
europepmc   +1 more source

Colorectal cancer cells respond differentially to autophagy induced by tyrosine kinase inhibitors. [PDF]

Sci Rep
Louadj L, Gerotziafas G, Sabbah M, Larsen AK.   +3 more
europepmc   +1 more source

Predictive factors for early mortality after regorafenib or trifluridine/tipiracil initiation in metastatic colorectal cancer. [PDF]

Oncologist
Masuishi T, Fukuoka S, Takashima A, Kumekawa Y, Yamazaki K, Yoshimura K, Moriwaki T.   +6 more
europepmc   +1 more source

Efficacy and Safety of Intensity-Modulated Radiotherapy Combined With Regorafenib With or Without Immune Checkpoint Inhibitors as Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Real-World Cohort Study From a Single Center. [PDF]

Cancer Med
Xin L, Li Z, Zhai Y, Wang L, Ye F, Sun Y, Zhang W, de Castria TB, Satapathy SK, Shelat VG, Mok SRS, Wu J, Wang S, Liu Y, Song Y, Tang Y, Jing H, Fang H, Qi S, Lu N, Li YX, Bi X, Chen B.   +22 more
europepmc   +1 more source

Comparative efficacy of therapeutic strategies for recurrent or refractory glioblastoma: a systematic review and network meta-analysis. [PDF]

Front Neurol
Zhang H, Sun L, Yun Z, Yin X, Li Y, Wu J, Dong G.   +6 more
europepmc   +1 more source

The SCD1 inhibitor aramchol interacts with regorafenib and metformin to kill tumor cells. [PDF]

Oncotarget
Booth MR, Booth L, Roberts JL, Kirkwood JM, Dent P.   +4 more
europepmc   +1 more source

A comprehensive analysis of the adverse drug events of metastatic and unresectable gastrointestinal stromal tumor treatment options: avapritinib, imatinib, regorafenib, ripretinib, and sunitinib safety insights and implications. [PDF]

Future Sci OA
Thompson CM, Andrews MB, Adler DG.
europepmc   +1 more source

Metastatic Colorectal Cancer Beyond Third-Line Treatment: Systematic Review and Meta-Analysis of Later-Line Therapies. [PDF]

J Clin Med
Giuliani J, Durante E, Mangiola D, Georgopulos A, Mantoan B, Fiorica F.   +5 more
europepmc   +1 more source